ArticleMarine drugs2021
Microalgae and Cyanobacteria Strains as Producers of Lipids with Antibacterial and Antibiofilm Activity.
Article in Marine drugs, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 57 citations in OpenAlex.
- A Thermosensitive Hydroxybutyl Chitosan/Microalgae Hydrogel With Antibacterial and Antioxidant Activities for Accelerating Burn Wound Healing.Macromolecular bioscience · 2026Article
- Bioactive Compounds from Microalgae and Cyanobacteria: Evaluation of Their Antioxidant and Antimicrobial Activities.Marine drugs · 2026Article
- Screening of 44 Baltic Sea Cyanobacterial Strains for Antibacterial and Quorum Sensing Inhibitory Potential: Selection of Promising Candidates.Antibiotics (Basel, Switzerland) · 2026Article
- Algal metabolites as emerging anti-virulence therapeutics against Pseudomonas aeruginosa.Archives of microbiology · 2025Review
- Arctic Diatoms as a Source of Antibiofilm Compounds: Identification of Methyl 3-Hydroxyoctadecanoate and PheophorbideBiomolecules · 2025Article
- Investigating the Impact of Cultivation Regimes on the Antibacterial Properties of Non-Polar Extracts of Chlorella sorokiniana and Anabaena sphaerica.Current microbiology · 2025Article
- Analytical Approaches to the Rapid Characterisation of Marine Glycolipids in Bioproduct Discovery.Marine drugs · 2025Review
- Microalgae: A Promising Source of Bioactive Polysaccharides for Biotechnological Applications.Molecules (Basel, Switzerland) · 2025Review
- Temporal and Depth-Driven Variability of Pelagic Bacterial Communities in Lake Erie: Biofilm and Plankton Dynamics.Environmental microbiology reports · 2025Article
- Marine Algae Polysaccharides: An Overview of Characterization Techniques for Structural and Molecular Elucidation.Marine drugs · 2025Review
- Synergistic effect of antibiotics, α-linolenic acid and solvent type against Staphylococcus aureus biofilm formation.Pharmacological reports : PR · 2024Article
- Biovalorization of whey waste as economic nutriment for mycogenic production of single cell oils with promising antibiofilm and anticancer potentiality.Journal of biological engineering · 2024Article
- How to fight acute sun damage? Current skin care strategies.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2024Article
- Quorum Quenching Approaches against Bacterial-Biofilm-Induced Antibiotic Resistance.Antibiotics (Basel, Switzerland) · 2024Review
- Anti-biofilm activity of marine algae-derived bioactive compounds.Frontiers in microbiology · 2024Review
- Marine MicroalgaeCurrent pharmaceutical biotechnology · 2024Article
- Study of the Antimicrobial Potential of theMarine drugs · 2023Article
- Seasonal Monitoring of Volatiles and Antioxidant Activity of Brown AlgaMarine drugs · 2023Article
- Cyclopropane-Containing Specialized Metabolites from the Marine Cyanobacterium cf.Molecules (Basel, Switzerland) · 2023Article
- Exploring Possible Ways to Enhance the Potential and Use of Natural Products through Nanotechnology in the Battle against Biofilms of Foodborne Bacterial Pathogens.Pathogens (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 5 institutions in 2 countries.
Funding
Abstract
Lipids are one of the primary metabolites of microalgae and cyanobacteria, which enrich their utility in the pharmaceutical, feed, cosmetic, and chemistry sectors. This work describes the isolation, structural elucidation, and the antibiotic and antibiofilm activities of diverse lipids produced by different microalgae and cyanobacteria strains from two European collections (ACOI and LEGE-CC). Three microalgae strains and one cyanobacteria strain were selected for their antibacterial and/or antibiofilm activity after the screening of about 600 strains carried out under the NoMorFilm European project. The total organic extracts were firstly fractionated using solid phase extraction methods, and the minimum inhibitory concentration and minimal biofilm inhibitory concentration against an array of human pathogens were determined. The isolation was carried out by bioassay-guided HPLC-DAD purification, and the structure of the isolated molecules responsible for the observed activities was determined by HPLC-HRESIMS and NMR methods. Sulfoquinovosyldiacylglycerol, monogalactosylmonoacylglycerol, sulfoquinovosylmonoacylglycerol, α-linolenic acid, hexadeca-4,7,10,13-tetraenoic acid (HDTA), palmitoleic acid, and lysophosphatidylcholine were found among the different active sub-fractions selected. In conclusion, cyanobacteria and microalgae produce a great variety of lipids with antibiotic and antibiofilm activity against the most important pathogens causing severe infections in humans. The use of these lipids in clinical treatments alone or in combination with antibiotics may provide an alternative to the current treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.